Analysis introduced on the European Respiratory Society Congress in Barcelona, Spain, has discovered that semaglutide, a glucagon-like peptide-1 receptor agonist used to deal with sort 2 diabetes and weight problems, can also scale back bronchial asthma assaults by as much as 40 per cent
Semaglutide – marketed worldwide as Ozempic and Wegovy – and extensively used to deal with sort 2 diabetes (T2DM) and in weight reduction has been proven to cut back bronchial asthma assaults by as much as 40 per cent, in line with analysis introduced on the European Respiratory Society (ERS) Congress in Barcelona, Spain.
The examine was led by Professor Chloe Bloom, scientific affiliate professor in respiratory epidemiology on the UK’s Nationwide Coronary heart and Lung Institute, Imperial School London, UK.
“Glucagon-like peptide-1 (GLP-1) receptor agonists are extensively used to deal with T2DM and weight problems. Earlier analysis means that they could have anti-inflammatory results and should enhance lung-related outcomes.
“Nevertheless, bronchial asthma and power obstructive pulmonary illness (COPD) outcomes haven’t been included as outcomes in GLP-1 drug trials.
“We needed to make use of real-world [evidence] well being data to research whether or not folks with bronchial asthma or COPD who began GLP-1 receptor agonists had fewer acute respiratory assaults,” mentioned Professor Bloom.
Inspecting UK digital medical data, the researchers carried out 4 parallel research, every of which checked out between 20,000 and 22,000 individuals who had began taking both a GLP-1 remedy or a unique class of diabetes remedy known as sulfonylureas.
The group discovered that individuals with airways ailments similar to bronchial asthma and COPD who had been prescribed GLP-1 therapies appeared to have fewer bronchial asthma assaults and COPD flare-ups than related individuals who had been prescribed different diabetes medicines.
“The impact was strongest with semaglutide, particularly in folks with bronchial asthma, the place use of semaglutide seems to be related to almost 40 per cent discount in bronchial asthma assaults. Semaglutide additionally led to a 20 per cent discount in COPD flare ups,” defined Professor Bloom.
She believes that for folks with airways illness who’re already eligible for GLP-1 receptor agonists due to weight problems or T2DM, the outcomes counsel these remedies could provide further respiratory advantages.
“The findings from this examine are encouraging however they need to not change remedy choices on their very own. Individuals with bronchial asthma or COPD shouldn’t begin GLP-1 receptor agonists particularly for his or her lung situation exterior present prescribing steering.
“Whereas the findings counsel that some folks taking GLP-1 receptor agonists could expertise fewer respiratory assaults this wants affirmation in scientific trials,” Bloom defined.
Dr Alexander Mathioudakis, Chair of the European Respiratory Society’s Group on Airway Pharmacology and Remedy and senior lecturer in respiratory drugs on the College of Manchester, UK, mentioned: “Weight problems and metabolic dysfunction are widespread in airways illness and are sometimes under-recognised as issues that may and needs to be addressed.
“This is likely one of the largest real-world research to research GLP-1 receptor agonists and airways illness and one of many first to look at whether or not results differ between particular person GLP-1 receptor agonists.
“It highlights the necessity to think about metabolic well being as a part of respiratory care. It additionally helps the case for together with respiratory outcomes, similar to bronchial asthma assaults and COPD exacerbations, in future trials of metabolic therapies.
“We’d like scientific trials that embody respiratory outcomes, similar to bronchial asthma assaults, COPD exacerbations, lung perform, signs and high quality of life, to find out whether or not metabolic remedies may turn into a part of a broader, extra personalised strategy to managing airways illness,” he added.
Mathioudakis was in a roundabout way concerned within the analysis.
For additional studying please see: European Respiratory Society Congress; summary no: OA5561 – ‘The differential effects of GLP-1 based therapies in airways disease’.
